

SEQUENCE LISTING

SEUNGUEN, JULIA CHO

<120> COMPOUNDS THAT ENHANCE TUMOR DEATH

<130> ARCD:351US

<140> 09/930,559

<141> 2001-08-15

<150> 60/225,526

<151> 2000-08-15

<160> 13

<170> PatentIn Ver. 2.1

<210> 1

<211> 2279

<212> DNA

<213> Human

<400> 1

ggcacgagcg aagatggcgt cgcccggctg cctgtggctc ttggctgtgg ctctcctgcc 60 atggacctgc gcttctcggg cgctgcagca tctggacccg ccggcgccgc tgccgttggt 120 gatctggcat gggatgggag acagctgttg caatccctta agcatgggtg ctattaaaaa 180 aatggtggag aagaaaatac ctggaattta cgtcttatct ttagagattg ggaagaccct 240 gatggaggac gtggagaaca gcttcttctt gaatgtcaat tcccaagtaa caacagtgtg 300 tcaqqcactt qctaaggatc ctaaattgca gcaaggctac aatgctatgg gattctccca 360 qqqaqqccaa tttctqaqqq caqtqqctca qaqatqccct tcacctccca tgatcaatct 420 gatctcggtt gggggacaac atcaaggtgt ttttggactc cctcgatgcc caggagagag 480 ctctcacatc tgtgacttca tccgaaaaac actgaatgct ggggcgtact ccaaagttgt 540 tcaggaacgc ctcgtgcaag ccgaatactg gcatgacccc ataaaggagg atgtgtatcg 600 caaccacage atettettgg cagatataaa teaggagegg ggtateaatg agteetacaa 660 qaaaaacctq atqqccctqa aqaaqtttqt gatqgtgaaa ttcctcaatg attccattgt 720 ggaccctgta gattcggagt ggtttggatt ttacagaagt ggccaagcca aggaaaccat 780 tecettacag gagacetece tgtacacaca ggacegeetg gggetaaagg aaatggacaa 840 tgcaggacag ctagtgtttc tggctacaga aggggaccat cttcagttgt ctgaagaatg 900 gttttatgcc cacatcatac cattccttgg atgaaacccg tatagttcac aatagagctc 960 agggagecce taactettee aaaccacatg ggagacagtt teetteatge ceaageetga 1020 qctcaqatcc agcttgcaac taatccttct atcatctaac atgcactact tggaaagatc 1080 taagatetga atettateet tigecatett etgttaeeat atggtgttga atgeaagitt 1140 aattaccatg gagattgttt tacaaacttt tgatgtggtc aagttcagtt ttagaaaagg 1200 gagtctgttc cagatcaggg ccagaactgt gcccaggccc aaaggagaca actaactaaa 1260 gtagtgagat agattctaag ggcaaacatt tttccaagtc ttgccatatt tcaagcaaag 1320 aggtgcccag gcctgaggta ctcacataaa tgctttgttt tgctggtgat ttaaccagtg 1380 cttggaaaaa tcttgcttgg ctattctgc atcattctt aaggctgcct tcctctcga 1440 gtacgttgcc ctctgtgcta tcaatcatct tatcatcaat tattagacaa atcccactgg 1500 cctacagtct tgcttctgca gcacccactt tgtctcctca ggtagtgatg aattagttgc 1560 tgtcacaaaa ggagggaagt agcacccaaa ttaaattgct taagagagga aatgtacatc 1620 ttgtataact tagggagcga agaaaatgta ggcgcgaaag tgaaaagtga ggcagctagt 1680 tcttcctatt ccattctcga ccaacctgcc ctttcttaat atgactagtg gtcttgatgc 1740 tagaggtcaac ttactctgt gctggcttta gcagagaata ggaggaacca tatgaaaaag 1800 atcaggctt ctgactcca tccccaaaac acatttacca gcatactcca aactgttct 1860 gatgtgttcc atgagaaaag gattgtttgc tcaaaaagct tggaaaatac tacacactcc 1920 ctttctcctt ctggagatca acccacatta gagtgtctaa ggactcctga gaattcctgt 1980 tacagtaaac aaaactaacg taatctacca tttcctacac tatttgagca tggaaatcat 2040 agtccccact ctatgaaaac ttaacgcttt ttggaagaca tttctgtagc atgtcagttt 2100 ggagaaatga tgagctacgc cttgatgaa gaaccgtgtt ggtgctgcta agtttagcca 2160 ttatggttt tccttctct ctcttctct ctcttaagcc ttattcttca actaaaagat gaggattaag 2220 agcaagaag tggggggat gtgaaaataa ttttatgagg ttgtctaaaa tctcgtgcc 2279

<210> 2

<211> 306

<212> PRT

<213> Human

<400> 2

Met Ala Ser Pro Gly Cys Leu Trp Leu Leu Ala Val Ala Leu Leu Pro 1 5 10 15

Trp Thr Cys Ala Ser Arg Ala Leu Gln His Leu Asp Pro Pro Ala Pro 20 25 30

Leu Pro Leu Val Ile Trp His Gly Met Gly Asp Ser Cys Cys Asn Pro 35 40 45

Leu Ser Met Gly Ala Ile Lys Lys Met Val Glu Lys Lys Ile Pro Gly 50 55 60

Ile Tyr Val Leu Ser Leu Glu Ile Gly Lys Thr Leu Met Glu Asp Val
65 70 75 80

Glu Asn Ser Phe Phe Leu Asn Val Asn Ser Gln Val Thr Thr Val Cys 85 90 95

Gln Ala Leu Ala Lys Asp Pro Lys Leu Gln Gln Gly Tyr Asn Ala Met 100 105 110

Gly Phe Ser Gln Gly Gly Gln Phe Leu Arg Ala Val Ala Gln Arg Cys 115 120 125

Pro Ser Pro Pro Met Ile Asn Leu Ile Ser Val Gly Gln His Gln

Gly Val Phe Gly Leu Pro Arg Cys Pro Gly Glu Ser Ser His Ile Cys

Asp Phe Ile Arg Lys Thr Leu Asn Ala Gly Ala Tyr Ser Lys Val Val

Gln Glu Arg Leu Val Gln Ala Glu Tyr Trp His Asp Pro Ile Lys Glu

Asp Val Tyr Arg Asn His Ser Ile Phe Leu Ala Asp Ile Asn Gln Glu

Arg Gly Ile Asn Glu Ser Tyr Lys Lys Asn Leu Met Ala Leu Lys Lys

Phe Val Met Val Lys Phe Leu Asn Asp Ser Ile Val Asp Pro Val Asp

Ser Glu Trp Phe Gly Phe Tyr Arg Ser Gly Gln Ala Lys Glu Thr Ile

Pro Leu Gln Glu Thr Ser Leu Tyr Thr Gln Asp Arg Leu Gly Leu Lys

Glu Met Asp Asn Ala Gly Gln Leu Val Phe Leu Ala Thr Glu Gly Asp

His Leu Gln Leu Ser Glu Glu Trp Phe Tyr Ala His Ile Ile Pro Phe

Leu Gly

<210> 3

<211> 7

<212> PRT

<213> Human

<400> 3

Gly Cys Val Lys Ile Lys Lys

<210> 4

<211> 8

```
<212> PRT
<213> Human
<400> 4
Ile Arg Tyr Cys Trp Leu Arg Arg
<210> 5
<211> 9
<212> PRT
<213> Human
<400> 5
Val Thr Thr Leu Cys Cys Gly Lys Asn
                5
<210> 6
<211> 7
<212> PRT
<213> Human
<400> 6
Met Leu Cys Cys Met Arg Arg
               5
<210> 7
<211> 8
<212> PRT
<213> Human
<400> 7
Met Gly Cys Leu Gly Asn Ser Lys
1
<210> 8
<211> 8
<212> PRT
<213> Human
<400> 8
Met Gly Cys Leu Gly Asn Ser Lys
                 5
```

```
<210> 9
<211> 10
<212> PRT
<213> Human
<400> 9
Gly Cys Met Ser Cys Lys Cys Val Leu Ser
                  5
<210> 10
<211> 35
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      Primer
<400> 10
tctaggtacc aagatggcgt cgcccggctg cctgt
                                                                    35
<210> 11
<211> 38
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      Primer
<400> 11
acggtctaga tcatccaagg aatggtatga tgtgggca
                                                                    38
<210> 12
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      Peptide
<400> 12
Val Lys Ile Lys Lys
  1
                  5
```